379 related articles for article (PubMed ID: 29604231)
1. Reframing the approach to patients with hepatocellular carcinoma: Longitudinal assessment with hazard associated with liver transplantation for HCC (HALTHCC) improves ablate and wait strategy.
Firl DJ; Kimura S; McVey J; Hashimoto K; Yeh H; Miller CM; Markmann JF; Sasaki K; Aucejo FN
Hepatology; 2018 Oct; 68(4):1448-1458. PubMed ID: 29604231
[TBL] [Abstract][Full Text] [Related]
2. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
3. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation.
Lee DD; Samoylova M; Mehta N; Musto KR; Roberts JP; Yao FY; Harnois DM
Liver Transpl; 2019 Feb; 25(2):228-241. PubMed ID: 30198150
[TBL] [Abstract][Full Text] [Related]
4. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
5. Waiting time predicts survival after liver transplantation for hepatocellular carcinoma: a cohort study using the United Network for Organ Sharing registry.
Schlansky B; Chen Y; Scott DL; Austin D; Naugler WE
Liver Transpl; 2014 Sep; 20(9):1045-56. PubMed ID: 24838471
[TBL] [Abstract][Full Text] [Related]
6. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
Mehta N; Sarkar M; Dodge JL; Fidelman N; Roberts JP; Yao FY
Liver Transpl; 2016 Feb; 22(2):178-87. PubMed ID: 26479422
[TBL] [Abstract][Full Text] [Related]
7. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
8. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.
Lee MW; Raman SS; Asvadi NH; Siripongsakun S; Hicks RM; Chen J; Worakitsitisatorn A; McWilliams J; Tong MJ; Finn RS; Agopian VG; Busuttil RW; Lu DSK
Hepatology; 2017 Jun; 65(6):1979-1990. PubMed ID: 28170115
[TBL] [Abstract][Full Text] [Related]
9. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy.
Mehta N; Dodge JL; Goel A; Roberts JP; Hirose R; Yao FY
Liver Transpl; 2013 Dec; 19(12):1343-53. PubMed ID: 24285611
[TBL] [Abstract][Full Text] [Related]
10. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
Lai Q; Inostroza M; Rico Juri JM; Goffette P; Lerut J
HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of the HALT-HCC score to predict mortality in liver transplant recipients with hepatocellular carcinoma: a retrospective cohort analysis.
Sasaki K; Firl DJ; Hashimoto K; Fujiki M; Diago-Uso T; Quintini C; Eghtesad B; Fung JJ; Aucejo FN; Miller CM
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):595-603. PubMed ID: 28546007
[TBL] [Abstract][Full Text] [Related]
12. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
Mehta N; Heimbach J; Lee D; Dodge JL; Harnois D; Burns J; Sanchez W; Roberts JP; Yao FY
Transplantation; 2017 Sep; 101(9):2071-2078. PubMed ID: 28353492
[TBL] [Abstract][Full Text] [Related]
13. The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria-In Patients Waiting for Liver Transplantation.
Lai Q; Vitale A; Iesari S; Finkenstedt A; Mennini G; Onali S; Hoppe-Lotichius M; Manzia TM; Nicolini D; Avolio AW; Mrzljak A; Kocman B; Agnes S; Vivarelli M; Tisone G; Otto G; Tsochatzis E; Rossi M; Viveiros A; Ciccarelli O; Cillo U; Lerut J;
Liver Transpl; 2019 Jul; 25(7):1023-1033. PubMed ID: 31087772
[TBL] [Abstract][Full Text] [Related]
14. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
[TBL] [Abstract][Full Text] [Related]
15. Significant Reduction in Posttransplant Hepatocellular Carcinoma Recurrence in the Post 6-Mo Waiting Policy Era.
Mahmud N; Yagan L; Hoteit MA; Reddy KR; Abt PL; Abu-Gazala S
Transplantation; 2024 May; 108(5):1172-1178. PubMed ID: 37953481
[TBL] [Abstract][Full Text] [Related]
16. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.
Goldaracena N; Gorgen A; Doyle A; Hansen BE; Tomiyama K; Zhang W; Ghanekar A; Lilly L; Cattral M; Galvin Z; Selzner M; Bhat M; Selzner N; McGilvray I; Greig PD; Grant DR; Sapisochin G
J Hepatol; 2019 Apr; 70(4):666-673. PubMed ID: 30630009
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
[TBL] [Abstract][Full Text] [Related]
18. Charting the Path Forward for Risk Prediction in Liver Transplant for Hepatocellular Carcinoma: International Validation of HALTHCC Among 4,089 Patients.
Firl DJ; Sasaki K; Agopian VG; Gorgen A; Kimura S; Dumronggittigule W; McVey JC; Iesari S; Mennini G; Vitale A; Finkenstedt A; Onali S; Hoppe-Lotichius M; Vennarecci G; Manzia TM; Nicolini D; Avolio AW; Agnes S; Vivarelli M; Tisone G; Ettorre GM; Otto G; Tsochatzis E; Rossi M; Viveiros A; Cillo U; Markmann JF; Ikegami T; Kaido T; Lai Q; Sapisochin G; Lerut J; ; Aucejo FN
Hepatology; 2020 Feb; 71(2):569-582. PubMed ID: 31243778
[TBL] [Abstract][Full Text] [Related]
19. A novel waitlist dropout score for hepatocellular carcinoma - identifying a threshold that predicts worse post-transplant survival.
Mehta N; Dodge JL; Roberts JP; Yao FY
J Hepatol; 2021 Apr; 74(4):829-837. PubMed ID: 33188904
[TBL] [Abstract][Full Text] [Related]
20. Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma.
Xing M; Sakaria S; Dhanasekaran R; Parekh S; Spivey J; Knechtle SJ; Zhang D; Kim HS
Cardiovasc Intervent Radiol; 2017 Mar; 40(3):410-420. PubMed ID: 27900445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]